Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of Dengue Tetravalent Vaccine (live, attenuated) in healthy subjects aged 4 to 60 years in India
2023-000134-15Phase 3
- Sponsor
- Takeda
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dengue fever comparing TDV vaccine arm with Placebo arm (2 arms). Primary endpoint: Number of Participants With Solicited Local Adverse Events (AEs) by Severity.
02
Drugs
dengue tetravalent vaccine, live, attenuated
03
Conditions
dengue fever
Beyond the preview
Go deeper on 2023-000134-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000134-15.